A committee of the European Medicines Agency has recommended approving Uplizna (inebilizumab-cdon) for adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for aquaporin-4 water channel autoantibodies (AQP4-IgG). This recommendation from the Committee for Medicinal Products for Human Use, known as CHMP, will now be reviewed by…
AQP4 autoantibodies
Recent Posts
- Real-world data show Enspryng reduces NMOSD relapses over 2.5 years
- How to power through each day, even if you’re living with NMOSD
- Estrogen may drive brain inflammation in NMOSD: Mouse study
- I may have the dragon fruit of diseases, but let’s not compare apples to oranges
- 17-year-old advocate shares her NMOSD story to raise awareness